Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
What the Aware Recovery Care sale actually means for SUD buyers
Buyers looking at Aware Recovery Care, or the next distressed multi-state SUD operator behind it, are inheriting a licensure, DEA, and payer-contract transition problem before they are inheriting a clinical business. That is the actual deal. The financial headline is straightforward: Behavioral Health Business reported that financial challenges at Aware Recovery Care have escalated, and new court filings suggest the Connecticut-based addiction treatment provider may soon have a new buyer or successor to continue operations at its clinics in 11 states.
The context matters. Aware Recovery Care raised a $35 million Series B round in 2023 to expand services and $3.5 million in 2024. The company was founded in 2011 but did not raise its growth equity until a decade later, in 2021, when it raised $22 million. A well-capitalized, Yale-affiliated in-home addiction treatment (IHAT) platform still ended up in an assignment for the benefit of creditors posture. Since June 1, 2026, Aware has failed to pay $23,911.75 in monthly rent. But court records show that Aware Recovery Care never filed a single legal response in its own eviction proceeding.
That is the tell. Founders and boards who wait until the eviction docket to name the problem lose control of the timeline. Buyers then inherit a compressed diligence window, a fragmented state licensure map, and a workforce being asked to sign new offer letters under duress. Operators evaluating this deal, or the next one, need a 90-day pre-LOI and post-LOI sequence built around licensure portability, DEA re-registration under 21 CFR 1301, 42 CFR Part 2 record custody, CMS Change of Ownership (CHOW) under 42 CFR 489.18, and payer contract assignability. Everything else is secondary.
The distress cycle in SUD M&A is real, and the numbers back it up
Aware is not an outlier. It is a data point on a curve the M&A advisors have been tracking for two years. Mertz Taggart’s Q4 2024 Behavioral Health M&A Report shows the SUD subsector still limping: Overall in 2024, 36 addiction treatment provider transactions were announced, a modest increase from 2023, which saw 29 deals, but still an unexpectedly low total and a far cry from the halcyon days of 2021, in which 79 transactions were completed.
The valuation and volume gap between 2021 and today is where distressed sellers live. Both M&A firms’ data show a steep drop-off from the peak of dealmaking in 2021: down 54%, according to Mertz Taggart, and 52%, according to the Braff Group. Buyers who sat out 2023 and 2024 are now looking at platforms that raised late-stage rounds at 2021 multiples and cannot service the resulting cost structure. Kevin Taggart of Mertz Taggart put the buyer psychology this way: “Buyers who had been sitting on the sidelines for a while reached out to us late in Q4 to catch up before the new year, and we’re starting to see some of the old buyers who haven’t been as active the past couple of years show interest in looking at deals again. That’s a positive sign.”
The math for a buyer of a distressed IHAT platform is not a growth story. It is a cost-to-cure calculation. What does it cost to keep the census intact across 11 state licensure jurisdictions while the assignee liquidates the debt? What is the delta between the asset purchase price and the working capital required to run parallel operations during CHOW? Most first-time buyers underestimate both numbers by half.
42 CFR Part 2, DEA registration, and CHOW: the three that break deals
Three regulatory items reliably blow up distressed SUD acquisitions. Buyers who do not have a plan for each before the LOI is signed will pay for it in the first 90 days post-close.
42 CFR Part 2 record custody. The 2024 Final Rule changed the calculus for buyers. According to HHS, In 2024, HHS published a final rule updating 42 CFR part 2 as required by the CARES Act. The Final Rule has been effective since April 16, 2024, and compliance was required by February 16, 2026. Enforcement authority now sits with OCR: On August 25, 2025, the HHS Secretary delegated to the Director of the Office for Civil Rights (OCR) the authority to administer and enforce Part 2. That means a buyer inheriting SUD records from a distressed seller inherits potential civil money penalty exposure if consent chains, patient notices, and QSO agreements are not documented. Diligence teams should map every Part 2 program, every consent form vintage, and every downstream disclosure recipient before the APA is signed.
DEA registration under 21 CFR 1301. DEA registrations are location-specific and do not automatically transfer in an asset purchase. If the target uses buprenorphine or other controlled substances at any site, the buyer’s timeline for a new DEA registration at each location, plus corresponding state controlled substance registrations, is the gating item for continuity of medication-assisted treatment. Buyers who assume they can operate under the seller’s registration during transition are creating a diversion risk they will not want to explain later.
CMS CHOW under 42 CFR 489.18. If any of the target’s programs bill Medicare or a Medicaid MCO that requires CHOW notification, expect a multi-month lag between close and the effective date of the new provider agreement. State Medicaid CHOWs vary widely, and in a distressed transaction, the buyer often operates under the seller’s provider number via a management services arrangement while the CHOW packet is under review. That MSA needs to be papered before close, not after.
Payer novation, licensure portability, and the IHAT wrinkle
An in-home addiction treatment model magnifies every multi-state problem. Aware operates across 11 states, which means 11 single state agencies (SSAs) for SUD licensure, 11 state Medicaid agencies, potentially dozens of MCO contracts, and a commercial credentialing footprint that touches every major national payer plus regional Blues plans. None of that transfers automatically.
Buyers need to build a payer contract matrix during diligence that flags three things per contract: assignability language (is consent required?), termination-on-change-of-control clauses, and timely filing implications during the transition. On the licensure side, buyers should treat every SSA as an independent regulator with its own change-of-ownership packet, its own fingerprinting cycle for new owners and clinical leadership, and its own survey window. Some states will require a full initial licensure review rather than a CHOW; others will treat it as an administrative amendment. The buyer who does not know the difference for each of the 11 states before signing will discover it after.
Accreditation transfer is the other layer. The Joint Commission and CARF both have change-of-ownership notification requirements and, depending on the structure, may require a re-survey. If the target holds a one-year accreditation with conditions, the buyer inherits both the conditions and the surveyor focus. Do not assume accreditation is a clean asset. Read the last survey report before you read the pro forma.
Finally, on the workforce: the Aware situation shows what happens when a seller pushes offer letters to clinical staff on a compressed timeline. Aware has been a defendant in an ongoing case since 2024 that seeks to recover wages on behalf of 290 past and present employees. But questions about its ability to pay the proposed settlement amount of $850,000 arose this summer after it failed to pay $23,911.75 in monthly rent at its 12,000-square-foot office headquarters since June. Buyers should assume wage-and-hour, WARN Act, and PTO liability questions will surface in the first 30 days post-close and reserve accordingly.
Frequently asked questions
How long does a Medicaid CHOW typically take when acquiring a multi-state SUD provider? There is no single national answer because each state Medicaid agency runs its own CHOW process under its interpretation of 42 CFR 489.18. Realistic planning ranges from 60 to 180 days per state, with some states requiring the buyer to enroll as a new provider entirely. For an 11-state platform, buyers should assume a rolling 6-to-12-month reimbursement transition and paper an interim management services arrangement with the seller or assignee to preserve cash flow.
What 42 CFR Part 2 issues arise during due diligence on a distressed addiction treatment operator? The big ones are consent chain integrity, QSO agreement documentation, and downstream disclosure logs. Because OCR enforces 42 CFR part 2. If OCR determines that a violation has occurred, OCR has a range of available remedies, including the imposition of a civil money penalty. Buyers should insist on written representations regarding Part 2 program status, obtain copies of the current patient notice, and quantify any consent gaps as a specific indemnity in the APA.
Can DEA registrations and state controlled substance licenses transfer with an asset purchase? Generally, no. DEA registrations under 21 CFR 1301 are issued to a specific registrant at a specific address. In an asset deal, the buyer must apply for a new registration at each location and, in parallel, secure new state controlled substance registrations. Buyers using MAT should build a DEA re-registration timeline into the closing checklist and consider a Power of Attorney arrangement for interim ordering only where the seller entity survives long enough to support it.
What are the biggest integration risks when acquiring an in-home addiction treatment (IHAT) model? Clinician licensure by state, mileage and travel-time reimbursement assumptions in the pro forma, EMR configuration for mobile documentation, HIPAA and Part 2 controls on personal devices, and payer credentialing for the specific place-of-service codes used. IHAT models look asset-light on the surface and become operationally dense once you audit the workflows.
How should operators evaluate payer contract assignability in a distressed SUD acquisition? Read every contract for anti-assignment and change-of-control language before you sign the LOI. Where the contract requires payer consent, start the notification process in parallel with the CHOW filings. Where the contract is silent, get written confirmation from the payer’s provider relations team that the assignment will be honored. And confirm that the seller’s utilization management authorizations for the existing census will remain valid post-close, or the first month’s revenue disappears.
References
- Behavioral Health Business: Aware Recovery Care’s Financial Troubles Worsen, Sales Talk Emerges (Sept 11, 2026)
- Behavioral Health Business: Aware Recovery Care Caught in Multiple Financial, Operational Crises (Aug 5, 2026)
- Mertz Taggart: Q4 2024 Behavioral Health M&A Report
- Behavioral Health Business: Addiction Treatment’s Dealmaking Doldrums (May 2025)
- HHS.gov: Understanding Confidentiality of Substance Use Disorder (SUD) Patient Records or “Part 2”
- APA: 42 CFR Part 2 Final Rule Overview